Suggested remit: To evaluate the benefits and costs of intrathechal idursulfase within its marketing authorisation for treating mucopolysaccharidosis type II for national commissioning by NHS England.
Status Awaiting development
Decision None selected
Process HST
ID number 1223

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
10 May 2018 - 08 June 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
14 May 2018 On receiving updated regulatory timing information from the company that markets the technology, NICE has agreed that holding a scoping workshop at this time would not be appropriate. Consequently the scoping workshop arranged for the 29 June 2018 will be cancelled and the consultation on the draft scope will not continue. The workshop and consultation will be rescheduled to take place in line with anticipated regulatory approval timings. We apologise for any inconvenience this may cause.

For further information on our processes and methods, please see our CHTE processes and methods manual